Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (732)	12/3/1999 5:09:00 PM
From: Dr. John M. de Castro	Respond to of 1494

Marc, the first abstract that I posted has to do with memantine's effectiveness with Parkinson's Disease (PD). PD is definitely a Merz indication. They've been marketing memantine in Germany for a number of years specifically for this indication. I posted it because it is part of the clinical case for the safety of memantine and its efficacy for neuroprotection. The second abstract has to do with neuroprotection after ischemia. It is arguable as to whether NTII or Merz has the primary rights here. The use patents that are the basis of NTII's portion of the pie do not include stroke. However, they do cover it when the ischemia is due to other reasons (eg TBI). Regardless, this is another indication of Memantine's safety and efficacy. The last abstract is really a very nice demonstration of the window of safety for memantine. For most drugs there is a dose window in which the drug is effective with minimal side effects. For some drugs the range is very tight and these drugs can be difficult and dangerous to administer. However, when the range is large, the drug becomes much more likely to be safe, even in the face of large individual differences in responsivity. All of these scientific publications are wonderful testimonials to the safety and effectiveness of memantine. When you're reliant on a single drug for your future, as NTII is, the drug had better be a good one. Memantine appears to be not just good, but remarkable. Have a great weekend John de C

To: JMarcus who wrote (732)	12/14/1999 5:10:00 PM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 1494

Very positive handwriting on the wall, eerrr, chart. NTII was scheduled to break the blind for the Neuropathic Pain Phase II clinical trial on the 8th of December. This means that who received Memantine and who received placebo is now known by the company and they are probably crunching the numbers even as you read this. They should have an announcement of the results before the end of the month. However, I'm sure the results for the primary endpoints have already been analyzed. In fact, they were probably analyzed within minutes of obtaining the list of Memantine and placebo patients. That means that NTII now knows whether Memantine worked or didn't. The preliminary, group data, that were discussed at the annual stockholders meeting were suggestive of a very positive outcome. (see my post #718 this thread). Todays trading pattern with a sharp rise on heavy volume in the face of a NASDAQ selloff, I see as extremely bullish. NTII, like most small companies, has been leaky in the past. I can speculate that todays NTII rally could be an indication of positive results. I can't overemphasize how important this would be for NTII. Neuropathic pain is a huge market and memantine will have to be taken on a chronic (continuous) basis by the sufferers and there is no alternative effective treatment available to relieve the suffering. NTII has, by agreement with Merz, the lions share of any profits or royalties earned on this indication. In other words, this is an immense potential profit machine for NTII. If the results are as positive as I anticipate, potential partners will line up to get in on this. Best regards John de C